Novo Nordisk considering sale of Ferrosan vitamin, OTC subsidiary.
This article was originally published in The Tan Sheet
Executive Summary
NOVO NORDISK CONSIDERING SALE OF FERROSAN VITAMIN/OTC BUSINESS, the Danish insulin and diabetes care products manufacturer ac-knowledged in a Sept. 25 release. Novo Nordisk said "an outright sale [of Ferrosan], as well as management buy-in and buy-out options, have been or are under consideration." Under a management buy-in, the company explained, a group from outside the company would purchase Ferrosan and run it.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning